Uterine Neoplasms, Version 1.2014

Restricted access

Adenocarcinoma of the endometrium (also known as endometrial cancer or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. An estimated 49,560 new uterine cancer cases will occur in 2013, with 8190 deaths resulting from the disease. Uterine sarcomas (stromal/mesenchymal tumors) are uncommon malignancies, accounting for approximately 3% of all uterine cancers. The NCCN Guidelines for Uterine Neoplasms describe malignant epithelial carcinomas and uterine sarcomas; each of these major categories contains specific histologic groups that require different management. This excerpt of these guidelines focuses on early-stage disease.

  • 1.

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:1130.

  • 2.

    D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010;116:131139.

  • 3.

    Van den Bosch T, Coosemans A, Morina M. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol 2012;26:257266.

  • 4.

    Kitchener HC, Trimble EL. Endometrial cancer state of the science meeting. Int J Gynecol Cancer 2009;19:134140.

  • 5.

    Dinkelspiel HE, Wright JD, Lewin SN, Herzog TJ. Contemporary clinical management of endometrial cancer. Obstet Gynecol Int 2013;2013:583891.

  • 6.

    Obermair A, Youlden DR, Young JP. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer 2010;127:26782684.

    • Search Google Scholar
    • Export Citation
  • 7.

    Katz VL. Diagnostic procedures. Imaging, endometrial sampling, endoscopy: indications and contraindications, complications. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM, eds. Comprehensive Gynecology, 5th ed. Philadelphia, PA: Mosby; 2007:Chapter 11.

    • Search Google Scholar
    • Export Citation
  • 8.

    Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol 2009;114:128134.

    • Search Google Scholar
    • Export Citation
  • 9.

    Kwon JS, Scott JL, Gilks CB. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011;29:22472252.

  • 10.

    Win AK, Lindor NM, Winship I. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst 2013;105:274279.

    • Search Google Scholar
    • Export Citation
  • 11.

    Lancaster JM, Powell CB, Kauff ND. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107:159162.

    • Search Google Scholar
    • Export Citation
  • 12.

    Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009;16:1422.

  • 13.

    Bonnet D, Selves J, Toulas C. Simplified identification of Lynch syndrome: a prospective, multicenter study. Dig Liver Dis 2012;44:515522.

  • 14.

    Walsh CS, Blum A, Walts A. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Gynecol Oncol 2010;116:516521.

    • Search Google Scholar
    • Export Citation
  • 15.

    Clarke BA, Cooper K. Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol 2012;19:231238.

    • Search Google Scholar
    • Export Citation
  • 16.

    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:3541.

    • Search Google Scholar
    • Export Citation
  • 17.

    Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin, in press.

    • Search Google Scholar
    • Export Citation
  • 18.

    Crispens MA. Endometrial and ovarian cancer in lynch syndrome. Clin Colon Rectal Surg 2012;25:97102.

  • 19.

    Manchanda R, Saridogan E, Abdelraheim A. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet 2012;286:15551562.

    • Search Google Scholar
    • Export Citation
  • 20.

    Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:47934797.

    • Search Google Scholar
    • Export Citation
  • 21.

    Schmeler KM, Lynch HT, Chen LM. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261269.

    • Search Google Scholar
    • Export Citation
  • 22.

    Creasman WT, Odicino F, Maisonneuve P. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S105143.

    • Search Google Scholar
    • Export Citation
  • 23.

    Lajer H, Elnegaard S, Christensen RD. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey. Acta Obstet Gynecol Scand 2012;91:976982.

    • Search Google Scholar
    • Export Citation
  • 24.

    Ueda SM, Kapp DS, Cheung MK. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008;198:218 e211-216.

    • Search Google Scholar
    • Export Citation
  • 25.

    Chan JK, Sherman AE, Kapp DS. Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 2011;29:832838.

    • Search Google Scholar
    • Export Citation
  • 26.

    McCluggage WG. My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol 2006;59:801812.

  • 27.

    McKenney JK, Longacre TA. Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. Adv Anat Pathol 2009;16:122.

    • Search Google Scholar
    • Export Citation
  • 28.

    Leitao MM Jr, Kehoe S, Barakat RR. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009;113:105108.

    • Search Google Scholar
    • Export Citation
  • 29.

    Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. Am J Obstet Gynecol 1988;158:489492.

    • Search Google Scholar
    • Export Citation
  • 30.

    Lee JH, Dubinsky T, Andreotti RF. ACR appropriateness Criteria pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q 2011;27:139145.

    • Search Google Scholar
    • Export Citation
  • 31.

    Ortashi O, Jain S, Emannuel O. Evaluation of the sensitivity, specificity, positive and negative predictive values of preoperative magnetic resonance imaging for staging endometrial cancer. A prospective study of 100 cases at the Dorset Cancer Centre. Eur J Obstet Gynecol Reprod Biol 2008;137:232235.

    • Search Google Scholar
    • Export Citation
  • 32.

    Crivellaro C, Signorelli M, Guerra L. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. Gynecol Oncol 2013;130:306311.

    • Search Google Scholar
    • Export Citation
  • 33.

    Kitajima K, Suzuki K, Senda M. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone? Ann Nucl Med 2011;25:511519.

    • Search Google Scholar
    • Export Citation
  • 34.

    Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:10971102.

  • 35.

    Duk JM, Aalders JG, Fleuren GJ. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol 1989;73:661668.

    • Search Google Scholar
    • Export Citation
  • 36.

    Patsner B, Orr JW Jr, Mann WJ Jr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 1990;162:427429.

    • Search Google Scholar
    • Export Citation
  • 37.

    Rose PG, Sommers RM, Reale FR. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 1994;84:1216.

    • Search Google Scholar
    • Export Citation
  • 38.

    Price FV, Chambers SK, Carcangiu ML. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer 1998;82:17201725.

    • Search Google Scholar
    • Export Citation
  • 39.

    Leslie KK, Thiel KW, Goodheart MJ. Endometrial cancer. Obstet Gynecol Clin North Am 2012;39:255268.

  • 40.

    Smith RA, Brooks D, Cokkinides V. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013;63:88105.

    • Search Google Scholar
    • Export Citation
  • 41.

    Boronow RC, Morrow CP, Creasman WT. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984;63:825832.

    • Search Google Scholar
    • Export Citation
  • 42.

    Cowles TA, Magrina JF, Masterson BJ, Capen CV. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol 1985;66:413416.

    • Search Google Scholar
    • Export Citation
  • 43.

    Creasman WT, Morrow CP, Bundy BN. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:20352041.

    • Search Google Scholar
    • Export Citation
  • 44.

    Benedet JL, Bender H, Jones H. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209262.

    • Search Google Scholar
    • Export Citation
  • 45.

    Wright JD, Barrena Medel NI, Sehouli J. Contemporary management of endometrial cancer. Lancet 2012;379:13521360.

  • 46.

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th edition. New York, NY: Springer; 2010.

  • 47.

    Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103104.

  • 48.

    Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009;105:109.

  • 49.

    Mariani A, Dowdy SC, Podratz KC. New surgical staging of endometrial cancer: 20 years later. Int J Gynaecol Obstet 2009;105:110111.

  • 50.

    Wethington SL, Barrena Medel NI, Wright JD, Herzog TJ. Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: unraveling a mystery. Gynecol Oncol 2009;115:1825.

    • Search Google Scholar
    • Export Citation
  • 51.

    Takeshima N, Nishida H, Tabata T. Positive peritoneal cytology in endometrial cancer: enhancement of other prognostic indicators. Gynecol Oncol 2001;82:470473.

    • Search Google Scholar
    • Export Citation
  • 52.

    ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005;106:413425.

    • Search Google Scholar
    • Export Citation
  • 53.

    Soliman PT, Frumovitz M, Spannuth W. Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol 2010;119:291294.

    • Search Google Scholar
    • Export Citation
  • 54.

    Kumar S, Mariani A, Bakkum-Gamez JN. Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol 2013;130:441445.

    • Search Google Scholar
    • Export Citation
  • 55.

    Kilgore LC, Partridge EE, Alvarez RD. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:2933.

    • Search Google Scholar
    • Export Citation
  • 56.

    Havrilesky LJ, Cragun JM, Calingaert B. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol 2005;99:689695.

    • Search Google Scholar
    • Export Citation
  • 57.

    Todo Y, Kato H, Kaneuchi M. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375:11651172.

    • Search Google Scholar
    • Export Citation
  • 58.

    Kitchener H, Swart AM, Qian Q. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125136.

    • Search Google Scholar
    • Export Citation
  • 59.

    Benedetti Panici P, Basile S, Maneschi F. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:17071716.

    • Search Google Scholar
    • Export Citation
  • 60.

    Seamon LG, Fowler JM, Cohn DE. Lymphadenectomy for endometrial cancer: the controversy. Gynecol Oncol 2010;117:68.

  • 61.

    Creasman WT, Mutch DE, Herzog TJ. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? Gynecol Oncol 2010;116:293294.

  • 62.

    Uccella S, Podratz KC, Aletti GD, Mariani A. Lymphadenectomy in endometrial cancer. Lancet 2009;373:1170; author reply 1170-1171.

  • 63.

    Uccella S, Podratz KC, Aletti GD, Mariani A. Re: systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2009;101:897898; author reply 898-899.

    • Search Google Scholar
    • Export Citation
  • 64.

    Milam MR, Java J, Walker JL. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol 2012;119:286292.

  • 65.

    Neubauer NL, Lurain JR. The role of lymphadenectomy in surgical staging of endometrial cancer. Int J Surg Oncol 2011;2011:814649.

  • 66.

    Daniel AG, Peters WA 3rd. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 1988;71:612614.

    • Search Google Scholar
    • Export Citation
  • 67.

    Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 1990;38:4648.

  • 68.

    Mariani A, Dowdy SC, Cliby WA. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:1118.

    • Search Google Scholar
    • Export Citation
  • 69.

    Hirahatake K, Hareyama H, Sakuragi N. A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol 1997;65:8287.

    • Search Google Scholar
    • Export Citation
  • 70.

    Frederick PJ, Straughn JM Jr. The role of comprehensive surgical staging in patients with endometrial cancer. Cancer Control 2009;16:2329.

    • Search Google Scholar
    • Export Citation
  • 71.

    Mori KM, Neubauer NL. Minimally invasive surgery in gynecologic oncology. ISRN Obstet Gynecol 2013;2013:312982.

  • 72.

    Mabrouk M, Frumovitz M, Greer M. Trends in laparoscopic and robotic surgery among gynecologic oncologists: a survey update. Gynecol Oncol 2009;112:501505.

    • Search Google Scholar
    • Export Citation
  • 73.

    Walker JL, Piedmonte MR, Spirtos NM. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009;27:53315336.

    • Search Google Scholar
    • Export Citation
  • 74.

    Walker JL, Piedmonte MR, Spirtos NM. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 2012;30:695700.

    • Search Google Scholar
    • Export Citation
  • 75.

    King LP, Miller DS. Recent progress: gynecologic oncology group trials in uterine corpus tumors. Rev Recent Clin Trials 2009;4:7074.

  • 76.

    Vergote I, Amant F, Neven P. Is it safe to treat endometrial carcinoma endoscopically? J Clin Oncol 2009;27:53055307.

  • 77.

    Mourits MJ, Bijen CB, Arts HJ. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 2010;11:763771.

    • Search Google Scholar
    • Export Citation
  • 78.

    Cho JE, Shamshirsaz AH, Nezhat C, Nezhat F. New technologies for reproductive medicine: laparoscopy, endoscopy, robotic surgery and gynecology. A review of the literature. Minerva Ginecol 2010;62:137167.

    • Search Google Scholar
    • Export Citation
  • 79.

    Seamon LG, Cohn DE, Henretta MS. Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy? Gynecol Oncol 2009;113:3641.

    • Search Google Scholar
    • Export Citation
  • 80.

    Boggess JF, Gehrig PA, Cantrell L. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol 2008;199:360 e361-369.

    • Search Google Scholar
    • Export Citation
  • 81.

    Bandera CA, Magrina JF. Robotic surgery in gynecologic oncology. Curr Opin Obstet Gynecol 2009;21:2530.

  • 82.

    Bell MC, Torgerson J, Seshadri-Kreaden U. Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques. Gynecol Oncol 2008;111:407411.

    • Search Google Scholar
    • Export Citation
  • 83.

    ElSahwi KS, Hooper C, De Leon MC. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecol Oncol 2012;124:260264.

    • Search Google Scholar
    • Export Citation
  • 84.

    Siesto G, Ornaghi S, Ieda N, Vitobello D. Robotic surgical staging for endometrial and cervical cancers in medically ill patients. Gynecol Oncol 2013;129:593597.

    • Search Google Scholar
    • Export Citation
  • 85.

    Jernigan AM, Auer M, Fader AN, Escobar PF. Minimally invasive surgery in gynecologic oncology: a review of modalities and the literature. Womens Health (Lond Engl) 2012;8:239250.

    • Search Google Scholar
    • Export Citation
  • 86.

    van Dam P, Hauspy J, Verkinderen L. Are costs of robot-assisted surgery warranted for gynecological procedures? Obstet Gynecol Int 2011;2011:973830.

    • Search Google Scholar
    • Export Citation
  • 87.

    Brudie LA, Backes FJ, Ahmad S. Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. Gynecol Oncol 2013;128:309315.

    • Search Google Scholar
    • Export Citation
  • 88.

    Backes FJ, Brudie LA, Farrell MR. Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecol Oncol 2012;125:546551.

    • Search Google Scholar
    • Export Citation
  • 89.

    Fleming ND, Ramirez PT. Robotic surgery in gynecologic oncology. Curr Opin Oncol 2012;24:547553.

  • 90.

    Weinberg L, Rao S, Escobar PF. Robotic surgery in gynecology: an updated systematic review. Obstet Gynecol Int 2011;2011:852061.

  • 91.

    Krill LS, Bristow RE. Robotic surgery: gynecologic oncology. Cancer J 2013;19:167176.

  • 92.

    Ramirez PT, Adams S, Boggess JF. Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology’s Clinical Practice Robotics Task Force. Gynecol Oncol 2012;124:180184.

    • Search Google Scholar
    • Export Citation
  • 93.

    Manfredi R, Mirk P, Maresca G. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 2004;231:372378.

    • Search Google Scholar
    • Export Citation
  • 94.

    Akin O, Mironov S, Pandit-Taskar N, Hann LE. Imaging of uterine cancer. Radiol Clin North Am 2007;45:167182.

  • 95.

    Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012;125:477482.

    • Search Google Scholar
    • Export Citation
  • 96.

    Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012;125:263270.

    • Search Google Scholar
    • Export Citation
  • 97.

    Gracia CR, Jeruss JS. Lives in the balance: women with cancer and the right to fertility care. J Clin Oncol 2013;31:668669.

  • 98.

    Ushijima K, Yahata H, Yoshikawa H. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:27982803.

    • Search Google Scholar
    • Export Citation
  • 99.

    Trimble CL, Method M, Leitao M. Management of endometrial precancers. Obstet Gynecol 2012;120:11601175.

  • 100.

    Mehasseb MK, Latimer JA. Controversies in the management of endometrial carcinoma: an update. Obstet Gynecol Int 2012;2012:676032.

  • 101.

    Hahn HS, Yoon SG, Hong JS. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009;19:10681073.

    • Search Google Scholar
    • Export Citation
  • 102.

    Park JY, Kim DY, Kim JH. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 2013;49:868874.

    • Search Google Scholar
    • Export Citation
  • 103.

    Park JY, Seong SJ, Kim TJ. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol 2013;121:136142.

    • Search Google Scholar
    • Export Citation
  • 104.

    Wright JD, Buck AM, Shah M. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009;27:12141219.

  • 105.

    Koskas M, Bendifallah S, Luton D. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril 2012;98:12291235.

    • Search Google Scholar
    • Export Citation
  • 106.

    Lee TS, Lee JY, Kim JW. Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study. Gynecol Oncol 2013;131:289293.

    • Search Google Scholar
    • Export Citation
  • 107.

    Fishman DA, Roberts KB, Chambers JT. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 1996;61:189196.

    • Search Google Scholar
    • Export Citation
  • 108.

    Coon D, Beriwal S, Heron DE. High-dose-rate Rotte “Y” applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. Int J Radiat Oncol Biol Phys 2008;71:779783.

    • Search Google Scholar
    • Export Citation
  • 109.

    Niazi TM, Souhami L, Portelance L. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys 2005;63:11081113.

    • Search Google Scholar
    • Export Citation
  • 110.

    Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006;58:242256.

    • Search Google Scholar
    • Export Citation
  • 111.

    Mountzios G, Pectasides D, Bournakis E. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol 2011;79:278292.

    • Search Google Scholar
    • Export Citation
  • 112.

    Fiorica JV, Brunetto VL, Hanjani P. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:1014.

    • Search Google Scholar
    • Export Citation
  • 113.

    Altman AD, Thompson J, Nelson G. Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J Obstet Gynaecol Can 2012;34:664672.

    • Search Google Scholar
    • Export Citation
  • 114.

    Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin 2009;25:11051109.

    • Search Google Scholar
    • Export Citation
  • 115.

    Rose PG, Brunetto VL, VanLe L. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000;78:212216.

    • Search Google Scholar
    • Export Citation
  • 116.

    Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007;17:964978.

    • Search Google Scholar
    • Export Citation
  • 117.

    Morrow CP, Bundy BN, Kurman RJ. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:5565.

    • Search Google Scholar
    • Export Citation
  • 118.

    Creutzberg CL, Nout RA. The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep 2011;13:472478.

  • 119.

    Neubauer NL, Havrilesky LJ, Calingaert B. The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol 2009;112:511516.

    • Search Google Scholar
    • Export Citation
  • 120.

    Gretz HFr, Economos K, Husain A. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol 1996;61:409415.

    • Search Google Scholar
    • Export Citation
  • 121.

    Ben-Shachar I, Pavelka J, Cohn DE. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 2005;105:487493.

    • Search Google Scholar
    • Export Citation
  • 122.

    Creutzberg CL, van Putten WL, Koper PC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:14041411.

    • Search Google Scholar
    • Export Citation
  • 123.

    Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419427.

    • Search Google Scholar
    • Export Citation
  • 124.

    Blake P, Swart AM, Orton J. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137146.

    • Search Google Scholar
    • Export Citation
  • 125.

    Keys HM, Roberts JA, Brunetto VL. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744751.

    • Search Google Scholar
    • Export Citation
  • 126.

    Creutzberg CL, van Putten WLJ, Wárlám-Rodenhuis CC. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004;22:12341241.

    • Search Google Scholar
    • Export Citation
  • 127.

    Scholten AN, van Putten WLJ, Beerman H. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834838.

    • Search Google Scholar
    • Export Citation
  • 128.

    Hockel M, Dornhofer N. Treatment of early endometrial carcinoma: is less more? Lancet 2009;373:9799.

  • 129.

    Creutzberg CL, Nout RA, Lybeert ML. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e631638.

    • Search Google Scholar
    • Export Citation
  • 130.

    Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2005;62:111117.

    • Search Google Scholar
    • Export Citation
  • 131.

    Nout RA, Smit VT, Putter H. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816823.

    • Search Google Scholar
    • Export Citation
  • 132.

    Small W Jr, Beriwal S, Demanes DJ. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 2012;11:5867.

    • Search Google Scholar
    • Export Citation
  • 133.

    Onsrud M, Cvancarova M, Hellebust TP. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol 2013;31:39513956.

    • Search Google Scholar
    • Export Citation
  • 134.

    Nout RA, Putter H, Jurgenliemk-Schulz IM. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012;48:16381648.

    • Search Google Scholar
    • Export Citation
  • 135.

    Roper B, Astner ST, Heydemann-Obradovic A. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol 2007;107:541548.

    • Search Google Scholar
    • Export Citation
  • 136.

    Nout RA, Putter H, Jurgenliemk-Schulz IM. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009;27:35473556.

    • Search Google Scholar
    • Export Citation
  • 137.

    McCloskey SA, Tchabo NE, Malhotra HK. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol 2010;116:404407.

    • Search Google Scholar
    • Export Citation
  • 138.

    Chino JP, Jones E, Berchuck A. The Influence of Radiation Modality and Lymph Node Dissection on Survival in Early-stage Endometrial Cancer. Int J Radiat Oncol Biol Phys 2012;82:18721879.

    • Search Google Scholar
    • Export Citation
  • 139.

    Lee CM, Szabo A, Shrieve DC. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 2006;295:389397.

    • Search Google Scholar
    • Export Citation
  • 140.

    Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007;114:13131320.

    • Search Google Scholar
    • Export Citation
  • 141.

    Kong A, Johnson N, Cornes P. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2007:CD003916.

  • 142.

    Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 2012;104:16251634.

    • Search Google Scholar
    • Export Citation
  • 143.

    Eifel PJ. The role of adjuvant radiation therapy for stage I endometrial cancer: does meta-analysis reveal the answer? J Natl Cancer Inst 2012;104:16151616.

    • Search Google Scholar
    • Export Citation
  • 144.

    Hogberg T, Signorelli M, de Oliveira CF. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer 2010;46:24222431.

    • Search Google Scholar
    • Export Citation
  • 145.

    Johnson N, Bryant A, Miles T. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011:CD003175.

  • 146.

    Le T, Menard C, Samant R. Longitudinal assessments of quality of life in endometrial cancer patients: effect of surgical approach and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2009;75:795802.

    • Search Google Scholar
    • Export Citation
  • 147.

    Salani R, Backes FJ, Fung MF. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466478.

    • Search Google Scholar
    • Export Citation
  • 148.

    Fung-Kee-Fung M, Dodge J, Elit L. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006;101:520529.

    • Search Google Scholar
    • Export Citation
  • 149.

    Greer BE, Goff BA, Koh WJ. Endometrial carcinoma. In: Johnson FE, Virgo KS, eds. Cancer Patient Follow-up. St. Louis: Mosby; 1997:357377.

  • 150.

    Bristow RE, Purinton SC, Santillan A. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol 2006;103:709713.

    • Search Google Scholar
    • Export Citation
  • 151.

    Cowens-Alvarado R, Sharpe K, Pratt-Chapman M. Advancing survivorship care through the National Cancer Survivorship Resource Center: developing American Cancer Society guidelines for primary care providers. CA Cancer J Clin 2013;63:147150.

    • Search Google Scholar
    • Export Citation
  • 152.

    McCabe MS, Bhatia S, Oeffinger KC. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 2013;31:631640.

    • Search Google Scholar
    • Export Citation
  • 153.

    Smith WA, Nolan VG, Robison LL. Physical activity among cancer survivors and those with no history of cancer—a report from the National Health and Nutrition Examination Survey 2003-2006. Am J Transl Res 2011;3:342350.

    • Search Google Scholar
    • Export Citation
  • 154.

    Cooper AL, Dornfeld-Finke JM, Banks HW. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer? Obstet Gynecol 2006;107:7176.

    • Search Google Scholar
    • Export Citation
  • 155.

    Salani R, Nagel CI, Drennen E, Bristow RE. Recurrence patterns and surveillance for patients with early stage endometrial cancer. Gynecol Oncol 2011;123:205207.

    • Search Google Scholar
    • Export Citation
  • 156.

    Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:11641167.

  • 157.

    Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:11671170.

  • 158.

    Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326330.

    • Search Google Scholar
    • Export Citation
  • 159.

    Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189191.

    • Search Google Scholar
    • Export Citation
  • 160.

    Chapman JA, DiSaia PJ, Osann K. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:11951200.

    • Search Google Scholar
    • Export Citation
  • 161.

    Barakat RR, Bundy BN, Spirtos NM. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:587592.

    • Search Google Scholar
    • Export Citation
  • 162.

    Chlebowski RT, Hendrix SL, Langer RD. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003;289:32433253.

    • Search Google Scholar
    • Export Citation
  • 163.

    Anderson GL, Limacher M, Assaf AR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:17011712.

    • Search Google Scholar
    • Export Citation
  • 164.

    LaCroix AZ, Chlebowski RT, Manson JE. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:13051314.

    • Search Google Scholar
    • Export Citation
  • 165.

    Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health 2010;2:123135.

    • Search Google Scholar
    • Export Citation
  • 166.

    Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. Oncologist 2011;16:16581664.

  • 167.

    Levine JP. Treating menopausal symptoms with a tissue-selective estrogen complex. Gend Med 2011;8:5768.

  • 168.

    Pinkerton JV, Utian WH, Constantine GD. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:11161124.

    • Search Google Scholar
    • Export Citation
  • 169.

    Loprinzi CL, Barton DL, Qin R. Nonestrogenic management of hot flashes. J Clin Oncol 2011;29:38423846.

  • 170.

    Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw 2010;8:11711179.

    • Search Google Scholar
    • Export Citation
  • 171.

    Castells MC, Tennant NM, Sloane DE. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574580.

    • Search Google Scholar
    • Export Citation
  • 172.

    Dizon DS, Sabbatini PJ, Aghajanian C. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84:378382.

    • Search Google Scholar
    • Export Citation
  • 173.

    Sampson HA, Munoz-Furlong A, Campbell RL. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373380.

    • Search Google Scholar
    • Export Citation
  • 174.

    Manivannan V, Decker WW, Stead LG. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med 2009;2:35.

    • Search Google Scholar
    • Export Citation
  • 175.

    Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601609.

  • 176.

    Markman M, Zanotti K, Peterson G. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:46114614.

    • Search Google Scholar
    • Export Citation
  • 177.

    Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99:393399.

    • Search Google Scholar
    • Export Citation
  • 178.

    Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004;95:370376.

    • Search Google Scholar
    • Export Citation
  • 179.

    Markman M, Hsieh F, Zanotti K. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 2004;130:2528.

    • Search Google Scholar
    • Export Citation
  • 180.

    Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;115:142153.

    • Search Google Scholar
    • Export Citation
  • 181.

    Olawaiye AB, Boruta DM 2nd. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;113:277283.

    • Search Google Scholar
    • Export Citation
  • 182.

    Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009;16:4652.

    • Search Google Scholar
    • Export Citation
  • 183.

    Varughese J, Hui P, Lu L. Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression. J Oncol 2011;2011:628084.

    • Search Google Scholar
    • Export Citation
  • 184.

    Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Mullerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 2009;7:550556; quiz 557.

    • Search Google Scholar
    • Export Citation
  • 185.

    Cirisano FD Jr, Robboy SJ, Dodge RK. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:5565.

    • Search Google Scholar
    • Export Citation
  • 186.

    Hendrickson MR, Longacre TA, Kempson RL. Uterine papillary serous carcinoma revisited. Gynecol Oncol 1994;54:261263.

  • 187.

    McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687690.

    • Search Google Scholar
    • Export Citation
  • 188.

    Cantrell LA, Havrilesky L, Moore DT. A multiinstitutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol 2012;127:2226.

    • Search Google Scholar
    • Export Citation
  • 189.

    Kanthan R, Senger JL. Uterine carcinosarcomas (malignant mixed mullerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int 2011;2011:470795.

    • Search Google Scholar
    • Export Citation
  • 190.

    D’Angelo E, Prat J. Pathology of mixed Mullerian tumours. Best Pract Res Clin Obstet Gynaecol 2011;25:705718.

  • 191.

    de Jong RA, Nijman HW, Wijbrandi TF. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol 2011;24:13681379.

    • Search Google Scholar
    • Export Citation
  • 192.

    Vorgias G, Fotiou S. The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet 2010;282:659664.

    • Search Google Scholar
    • Export Citation
  • 193.

    Fader AN, Drake RD, O’Malley DM. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 2009;115:21192127.

    • Search Google Scholar
    • Export Citation
  • 194.

    Fader AN, Nagel C, Axtell AE. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol 2009;112:558562.

    • Search Google Scholar
    • Export Citation
  • 195.

    Vandenput I, Trovik J, Vergote I. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study. Int J Gynecol Cancer 2011;21:332336.

    • Search Google Scholar
    • Export Citation
  • 196.

    Kelly MG, O’Malley D M, Hui P. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005;98:353359.

    • Search Google Scholar
    • Export Citation
  • 197.

    Thomas MB, Mariani A, Cliby WA. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;107:186189.

    • Search Google Scholar
    • Export Citation
  • 198.

    Goldberg H, Miller RC, Abdah-Bortnyak R. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol 2008;108:298305.

    • Search Google Scholar
    • Export Citation
  • 199.

    Hamilton CA, Cheung MK, Osann K. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol 2006;103:679683.

    • Search Google Scholar
    • Export Citation
  • 200.

    Grice J, Ek M, Greer B. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998;69:6973.

    • Search Google Scholar
    • Export Citation
  • 201.

    Havrilesky LJ, Secord AA, Bae-Jump V. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;105:677682.

  • 202.

    Sutton G, Axelrod JH, Bundy BN. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;100:349354.

    • Search Google Scholar
    • Export Citation
  • 203.

    Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol 2010;22:2129.

    • Search Google Scholar
    • Export Citation
  • 204.

    Homesley HD, Filiaci V, Markman M. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:526531.

    • Search Google Scholar
    • Export Citation
  • 205.

    Einstein MH, Frimer M, Kuo DY. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecol Oncol 2012;124:2125.

    • Search Google Scholar
    • Export Citation
  • 206.

    Randall ME, Filiaci VL, Muss H. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:3644.

    • Search Google Scholar
    • Export Citation
  • 207.

    Galaal K, van der Heijden E, Godfrey K. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2013;2:CD006812.

    • Search Google Scholar
    • Export Citation
  • 208.

    Wang W, Do V, Hogg R. Uterine papillary serous carcinoma: patterns of failure and survival. Aust N Z J Obstet Gynaecol 2009;49:419425.

  • 209.

    Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;57:10041009.

    • Search Google Scholar
    • Export Citation
  • 210.

    Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;55:12721276.

    • Search Google Scholar
    • Export Citation
  • 211.

    Sood BM, Jones J, Gupta S. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 2003;57:208216.

    • Search Google Scholar
    • Export Citation
  • 212.

    Wolfson AH, Brady MF, Rocereto T. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177185.

    • Search Google Scholar
    • Export Citation
  • 213.

    Sutton G, Brunetto VL, Kilgore L. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol 2000;79:147153.

    • Search Google Scholar
    • Export Citation
  • 214.

    Hensley ML. Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas. Best Pract Res Clin Obstet Gynaecol 2011;25:773782.

    • Search Google Scholar
    • Export Citation
  • 215.

    Sutton G, Kauderer J, Carson LF. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:630634.

    • Search Google Scholar
    • Export Citation
  • 216.

    Powell MA, Filiaci VL, Rose PG. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol 2010;28:27272731.

    • Search Google Scholar
    • Export Citation
  • 217.

    Reed NS, Mangioni C, Malmström H. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808818.

    • Search Google Scholar
    • Export Citation
  • 218.

    Callister M, Ramondetta LM, Jhingran A. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786796.

    • Search Google Scholar
    • Export Citation
  • 219.

    Chi DS, Mychalczak B, Saigo PE. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997;65:493498.

    • Search Google Scholar
    • Export Citation
  • 220.

    Knocke TH, Weitmann HD, Kucera H. Results of primary and adjuvant radiotherapy in the treatment of mixed Müllerian tumors of the corpus uteri. Gynecol Oncol 1999;73:389395.

    • Search Google Scholar
    • Export Citation
  • 221.

    Larson B, Silfverswärd C, Nilsson B, Pettersson F. Mixed müllerian tumours of the uterus—prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 1990;17:123132.

    • Search Google Scholar
    • Export Citation
  • 222.

    Gerszten K, Faul C, Kounelis S. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998;68:813.

  • 223.

    Dusenbery KE, Potish RA, Argenta PA, Judson PL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol 2005;28:295300.

    • Search Google Scholar
    • Export Citation
  • 224.

    Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008;111:8288.

    • Search Google Scholar
    • Export Citation
  • 225.

    Lee CH, Marino-Enriquez A, Ou W. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012;36:641653.

    • Search Google Scholar
    • Export Citation
  • 226.

    Lee CH, Ou WB, Marino-Enriquez A. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A 2012;109:929934.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 434 341 44
PDF Downloads 76 57 2
EPUB Downloads 0 0 0